Wealth Enhancement Advisory Services LLC Reduces Stake in Apyx Medical Co. (NASDAQ:APYX)

Wealth Enhancement Advisory Services LLC cut its holdings in shares of Apyx Medical Co. (NASDAQ:APYX) by 42.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 90,798 shares of the company’s stock after selling 67,148 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.26% of Apyx Medical worth $113,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of APYX. Rathbones Group PLC increased its stake in shares of Apyx Medical by 148.0% in the second quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after acquiring an additional 150,000 shares during the period. RPg Family Wealth Advisory LLC purchased a new position in shares of Apyx Medical during the 2nd quarter valued at about $101,000. Kingsview Wealth Management LLC lifted its holdings in shares of Apyx Medical by 156.7% in the 1st quarter. Kingsview Wealth Management LLC now owns 31,028 shares of the company’s stock valued at $42,000 after buying an additional 18,943 shares during the period. Perkins Capital Management Inc. boosted its stake in shares of Apyx Medical by 7.0% in the first quarter. Perkins Capital Management Inc. now owns 228,500 shares of the company’s stock worth $311,000 after buying an additional 15,000 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Apyx Medical by 2.9% during the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after acquiring an additional 14,481 shares during the period. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Stock Performance

NASDAQ APYX opened at $1.37 on Wednesday. The stock has a market capitalization of $47.46 million, a price-to-earnings ratio of -1.65 and a beta of 1.21. The stock has a 50-day moving average of $1.21 and a 200 day moving average of $1.33. The company has a current ratio of 5.33, a quick ratio of 4.45 and a debt-to-equity ratio of 2.26. Apyx Medical Co. has a twelve month low of $0.97 and a twelve month high of $3.26.

Apyx Medical (NASDAQ:APYX) last announced its earnings results on Friday, November 8th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. Apyx Medical had a negative return on equity of 105.45% and a negative net margin of 57.86%. The business had revenue of $11.49 million during the quarter, compared to the consensus estimate of $11.66 million. During the same period in the prior year, the company posted ($0.13) EPS. Sell-side analysts anticipate that Apyx Medical Co. will post -0.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on APYX. Craig Hallum raised Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th. JMP Securities reissued a “market perform” rating on shares of Apyx Medical in a report on Monday, September 16th. Finally, BTIG Research assumed coverage on shares of Apyx Medical in a research report on Thursday, October 17th. They set a “neutral” rating on the stock.

Apyx Medical Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.